{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:46:28Z","timestamp":1792820788624,"version":"4.5.0"},"reference-count":227,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["L1 Investigator Grant APP2034406"],"award-info":[{"award-number":["L1 Investigator Grant APP2034406"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14760584.2025.2609869","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T19:06:51Z","timestamp":1766603211000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Global status of HPV vaccination two decades in: effective, safe and preventing cancer"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-3105","authenticated-orcid":false,"given":"Julia M. L.","family":"Brotherton","sequence":"first","affiliation":[{"name":"The University of Melbourne","place":["Parkville, Australia"]},{"name":"National Centre for Immunisation Research and Surveillance","place":["Westmead, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8392-5790","authenticated-orcid":false,"given":"D. Scott","family":"LaMontagne","sequence":"additional","affiliation":[{"name":"International Division, JSI","place":["Arlington, USA"]},{"name":"University of Washington","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-5325","authenticated-orcid":false,"given":"Paul J. N.","family":"Bloem","sequence":"additional","affiliation":[{"name":"World Health Organization","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc798"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"issue":"4","key":"e_1_3_5_5_1","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/infdis\/jiaa621","article-title":"Human papillomavirus vaccines","volume":"224","author":"Markowitz LE","year":"2021","unstructured":"Markowitz LE, Schiller JT. Human papillomavirus vaccines. J Infect Dis. 2021;224(Suppl 4):S367\u201378.","journal-title":"J Infect Dis"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.12.079"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.13"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1591297"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2017.08.015"},{"key":"e_1_3_5_10_1","first-page":"1","article-title":"Biological agents. Volume 100 B. A review of human carcinogens","volume":"100","author":"International Agency for Research on Cancer","year":"2012","unstructured":"International Agency for Research on Cancer. Biological agents. Volume 100 B. A review of human carcinogens. Iarc Monogr Eval Carcinog Risks Hum. 2012;100(PT B):1.","journal-title":"Iarc Monogr Eval Carcinog Risks Hum"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01097-3"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2017.08.006"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.06.015"},{"issue":"1","key":"e_1_3_5_14_1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines - a review of the first decade","volume":"146","author":"Harper DM","year":"2017","unstructured":"Harper DM, DeMars LR. HPV vaccines - a review of the first decade. Gynecol Oncol. 2017;146(1):196\u2013204.","journal-title":"Gynecol Oncol"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.108"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71073-4"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30298-3"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0039-5"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0625-z"},{"issue":"28","key":"e_1_3_5_20_1","first-page":"393","article-title":"Meeting of the global advisory committee on vaccine safety, 7\u20138 June 2017","volume":"92","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Meeting of the global advisory committee on vaccine safety, 7\u20138 June 2017. Releve Epidemiol Hebd. 2017;92(28):393\u2013402.","journal-title":"Releve Epidemiol Hebd"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909537"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-4144"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.36121"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70187-1"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70225-5"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70841-2"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix476"},{"issue":"2","key":"e_1_3_5_28_1","first-page":"208","article-title":"A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program","volume":"217","author":"Novakovic D","year":"2018","unstructured":"Novakovic D, Cheng ATL, Zurynski Y, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018;217(2):208\u2013212.","journal-title":"J Infect Dis"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.089862"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines3020408"},{"issue":"12","key":"e_1_3_5_31_1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study","volume":"7","author":"Romanowski B","year":"2011","unstructured":"Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374\u20131386.","journal-title":"Hum Vaccin"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1625"},{"issue":"43","key":"e_1_3_5_33_1","first-page":"465","article-title":"Human papillomavirus vaccines: WHO position paper, October 2014","volume":"89","author":"World Health Organization","year":"2014","unstructured":"World Health Organization.Human papillomavirus vaccines: WHO position paper, October 2014. Releve Epidemiol Hebd. 2014;89(43):465\u2013491.","journal-title":"Releve Epidemiol Hebd"},{"key":"e_1_3_5_34_1","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. 2020. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240014107"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30157-4"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30068-4"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-03897-3"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00241-8"},{"issue":"1","key":"e_1_3_5_39_1","doi-asserted-by":"crossref","first-page":"e000726","DOI":"10.1136\/bmjmed-2023-000726","article-title":"Covid-19 pandemic and equity of global human papillomavirus vaccination: descriptive study of World Health Organization-unicef vaccination coverage estimates","volume":"3","author":"Casey RM","year":"2024","unstructured":"Casey RM, Akaba H, Hyde TB, et al. Covid-19 pandemic and equity of global human papillomavirus vaccination: descriptive study of World Health Organization-unicef vaccination coverage estimates. BMJ Med. 2024;3(1). Available from e000726. Available from: https:\/\/bmjmedicine.bmj.com\/content\/3\/1\/e000726","journal-title":"BMJ Med"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgae026"},{"key":"e_1_3_5_41_1","unstructured":"Human papillomavirus vaccines: WHO position paper. [cited 2022 Dec]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/who-wer9750-645-672."},{"key":"e_1_3_5_42_1","unstructured":"IARC HPV Working Group. Primary End-points for Prophylactic HPV Vaccine Trials [Internet]. Lyon FR: International Agency for Research on Cancer; 2014 [cited 2025 Sep 7]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK304971\/"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00047-9"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa011"},{"issue":"3","key":"e_1_3_5_45_1","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1016\/S2214-109X(23)00586-7","article-title":"Comparing one dose of HPV vaccine in girls aged 9\u201314 years in Tanzania (DoRIS) with one dose in young women aged 15\u201320 years in Kenya (KEN she): an immunobridging analysis of randomised controlled trials","volume":"12","author":"Baisley K","year":"2024","unstructured":"Baisley K, Kemp TJ, Mugo NR, et al. Comparing one dose of HPV vaccine in girls aged 9\u201314 years in Tanzania (DoRIS) with one dose in young women aged 15\u201320 years in Kenya (KEN she): an immunobridging analysis of randomised controlled trials. Lancet Glob Health. 2024;12(3):e491\u20139.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"e_1_3_5_46_1","doi-asserted-by":"crossref","first-page":"EVIDoa2100056","DOI":"10.1056\/EVIDoa2100056","article-title":"Efficacy of single-dose HPV vaccination among young African women","volume":"1","author":"Barnabas RV","year":"2022","unstructured":"Barnabas RV, Brown ER, Onono MA, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 2022;1(5):EVIDoa2100056.","journal-title":"NEJM Evid"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02658-0"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2024.100486"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgae032"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00453-8"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgae042"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2506765"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2414514122"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(23)00180-9"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgae037"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgae039"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127475"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.05.039"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2017.08.010"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw354"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12186"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917338"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab080"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101327"},{"issue":"5","key":"e_1_3_5_65_1","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/03036758.2025.2458028","article-title":"Realising the promise of HPV vaccination - data from the national cervical screening and vaccination registers demonstrates the impact of HPV vaccination in Aotearoa New Zealand","volume":"55","author":"Sykes P","year":"2025","unstructured":"Sykes P, Innes C, Simcock B, et al. Realising the promise of HPV vaccination - data from the national cervical screening and vaccination registers demonstrates the impact of HPV vaccination in Aotearoa New Zealand. J R Soc N Z. 2025;55(5):1271\u20131283.","journal-title":"J R Soc N Z"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02178-4"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad263"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050669"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.22169"},{"issue":"1","key":"e_1_3_5_70_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1055-9965.EPI-20-0846","article-title":"Assessing impact of HPV vaccination on cervical cancer incidence among women aged 15\u201329 years in the United States, 1999\u20132017: an ecologic study","volume":"30","author":"Mix JM","year":"2021","unstructured":"Mix JM, Van Dyne EA, Saraiya M, et al. Assessing impact of HPV vaccination on cervical cancer incidence among women aged 15\u201329 years in the United States, 1999\u20132017: an ecologic study. Cancer Epidemiol Biomark Prev. 2021;30(1):30\u201337.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"e_1_3_5_71_1","unstructured":"Smith M Brotherton J Machalek D et al. 2025 cervical cancer elimination progress report: Australia\u2019s progress towards the elimination of cervical cancer as a public health problem [Internet]. Melbourne (AU); 2025 [cited 2025 Nov 24]. Available from: https:\/\/www.cervicalcancercontrol.org.au"},{"issue":"10","key":"e_1_3_5_72_1","doi-asserted-by":"crossref","first-page":"e1715","DOI":"10.1016\/S2214-109X(25)00279-7","article-title":"Effect of Brazil\u2019s national human papillomavirus vaccination programme on the incidence of cervical cancer and cervical intraepithelial neoplasia grade 3 in women aged 20\u201324 years: a population-based study","volume":"13","author":"Cerqueira-Silva T","year":"2025","unstructured":"Cerqueira-Silva T, Barral-Netto M, Boaventura VS. Effect of Brazil\u2019s national human papillomavirus vaccination programme on the incidence of cervical cancer and cervical intraepithelial neoplasia grade 3 in women aged 20\u201324 years: a population-based study. Lancet Glob Health. 2025;13(10):e1715\u201322.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"e_1_3_5_73_1","doi-asserted-by":"crossref","first-page":"pkad016","DOI":"10.1093\/jncics\/pkad016","article-title":"Incidence of human papillomavirus-related cancers among males and females aged 15\u201334 years in the United States","volume":"7","author":"Guo F","year":"2023","unstructured":"Guo F, Adekanmbi V, Hsu CD, et al. Incidence of human papillomavirus-related cancers among males and females aged 15\u201334 years in the United States. JNCI Cancer Spectr. 2023;7(2):pkad016.","journal-title":"JNCI Cancer Spectr"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.926555"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81459"},{"key":"e_1_3_5_76_1","doi-asserted-by":"crossref","first-page":"107302","DOI":"10.1016\/j.ypmed.2022.107302","article-title":"Trends in HPV- and non-HPV-associated vulvar cancer incidence, United States, 2001\u20132017","volume":"164","author":"Mix JM","year":"2022","unstructured":"Mix JM, Gopalani SV, Simko S, et al. Trends in HPV- and non-HPV-associated vulvar cancer incidence, United States, 2001\u20132017. Prev Med. 2022;164:107302.","journal-title":"Prev Med"},{"issue":"11","key":"e_1_3_5_77_1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1940-6207.CAPR-22-0086","article-title":"Vulvar cancer incidence in the United States and its relationship to human papillomavirus vaccinations, 2001\u20132018","volume":"15","author":"Berenson AB","year":"2022","unstructured":"Berenson AB, Chang M, Hawk ET, et al. Vulvar cancer incidence in the United States and its relationship to human papillomavirus vaccinations, 2001\u20132018. Cancer Prev Res Phila Pa. 2022;15(11):777\u2013784.","journal-title":"Cancer Prev Res Phila Pa"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7652"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae096"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33185"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101178"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz239"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2019.100177"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz555"},{"issue":"3","key":"e_1_3_5_85_1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ijc.32340","article-title":"Cervical adenocarcinoma in situ: human papillomavirus types and incidence trends in five states, 2008\u20132015","volume":"146","author":"Cleveland AA","year":"2020","unstructured":"Cleveland AA, Gargano JW, Park IU, et al. Cervical adenocarcinoma in situ: human papillomavirus types and incidence trends in five states, 2008\u20132015. Int J Cancer. 2020;146(3):810\u2013818.","journal-title":"Int J Cancer"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf055"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16429"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101203"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae209"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2514949"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-024-07692-y"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-0895"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14682"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106641"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa209"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad189"},{"issue":"1","key":"e_1_3_5_97_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amepre.2021.06.026","article-title":"Vaginal, and anal precancers among U.S. adolescents and young adults after human papillomavirus vaccine introduction","volume":"62","author":"Mix JM","year":"2022","unstructured":"Mix JM, Saraiya M, Senkomago V, et al. Vaginal, and anal precancers among U.S. adolescents and young adults after human papillomavirus vaccine introduction. Am J Prev Med. 2022;62(1):95\u201399.","journal-title":"Am J Prev Med"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt032"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit436"},{"key":"e_1_3_5_100_1","doi-asserted-by":"crossref","first-page":"108165","DOI":"10.1016\/j.ypmed.2024.108165","article-title":"Human papillomavirus-associated cancers, precancers, and genital warts in Denmark, 2000\u20132022 - current burden of disease and population impact of multi-cohort HPV vaccination","volume":"189","author":"Kaderly Rasmussen EL","year":"2024","unstructured":"Kaderly Rasmussen EL, Lindquist S, Baandrup L, et al. Human papillomavirus-associated cancers, precancers, and genital warts in Denmark, 2000\u20132022 - current burden of disease and population impact of multi-cohort HPV vaccination. Prev Med. 2024;189:108165.","journal-title":"Prev Med"},{"key":"e_1_3_5_101_1","unstructured":"King J Kwon J McManus H et al. HIV viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2024: sexually transmissible infections [Internet]. Sydney (AU): The Kirby Institute UNSW Sydney ; 2024 [cited 2025 Sep 13]. Available from: https:\/\/www.kirby.unsw.edu.au\/sites\/default\/files\/documents\/Annual_Surveillance_Report_2024_STI_1.pdf"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf052"},{"issue":"1339","key":"e_1_3_5_103_1","first-page":"51","article-title":"Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health services","volume":"124","author":"Oliphant J","year":"2011","unstructured":"Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health services. N Z Med J. 2011;124(1339):51\u201358.","journal-title":"N Z Med J"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2024040"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.07.031"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.11.070"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132404"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267646"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000948"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2018-053751"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106166"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab171"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2025.49.019"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.10.002"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278477"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf032"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.27.2400820"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30468-1"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae327"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127576"},{"issue":"10","key":"e_1_3_5_121_1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/OLQ.0000000000002192","article-title":"Human papillomavirus vaccine effectiveness by age, age at vaccination, and timing of vaccination relative to age at first sex among men who have sex with men-Seattle, Washington, 2018 to 2020","volume":"52","author":"Buchbinder SA","year":"2025","unstructured":"Buchbinder SA, Lin J, Markowitz LE, et al. Human papillomavirus vaccine effectiveness by age, age at vaccination, and timing of vaccination relative to age at first sex among men who have sex with men-Seattle, Washington, 2018 to 2020. Sex Transm Dis. 2025;52(10):631\u2013640.","journal-title":"Sex Transm Dis"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003691"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30687-3"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10284-5"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1204101"},{"issue":"1","key":"e_1_3_5_126_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1158\/1940-6207.CAPR-21-0063","article-title":"Reduction in vaccine HPV type infections in a young women group (18\u201325 years) five years after HPV vaccine introduction in Colombia","volume":"15","author":"Combita AL","year":"2022","unstructured":"Combita AL, Reyes V, Puerto D, et al. Reduction in vaccine HPV type infections in a young women group (18\u201325 years) five years after HPV vaccine introduction in Colombia. Cancer Prev Res Phila Pa. 2022;15(1):55\u201366.","journal-title":"Cancer Prev Res Phila Pa"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-2849"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00193-6"},{"issue":"1","key":"e_1_3_5_129_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid2701.191364","article-title":"Impact of human papillomavirus vaccination, Rwanda and Bhutan","volume":"27","author":"Baussano I","year":"2021","unstructured":"Baussano I, Sayinzoga F, Tshomo U, et al. Impact of human papillomavirus vaccination, Rwanda and Bhutan. Emerg Infect Dis. 2021;27(1):1\u20139.","journal-title":"Emerg Infect Dis"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae455"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100798"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15010159"},{"key":"e_1_3_5_133_1","unstructured":"World Health Organization. Safety of HPV vaccines [Internet]. [cited 2025 Sep 14]. Available from: https:\/\/www.who.int\/groups\/global-advisory-committee-on-vaccine-safety\/topics\/human-papillomavirus-vaccines\/safety"},{"issue":"1","key":"e_1_3_5_134_1","doi-asserted-by":"crossref","first-page":"2184756","DOI":"10.1080\/21645515.2023.2184756","article-title":"Post-marketing surveillance study of the safety of the HPV-16\/18 vaccine in Korea (2017\u20132021)","volume":"19","author":"Eun BW","year":"2023","unstructured":"Eun BW, Bahar E, Xavier S, et al. Post-marketing surveillance study of the safety of the HPV-16\/18 vaccine in Korea (2017\u20132021). Hum Vaccines Immunother. 2023;19(1):2184756.","journal-title":"Hum Vaccines Immunother"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.039"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2539590"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2315653"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.4.2001619"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002569"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13040391"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2019.05.002"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2024-000854"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015363.pub2"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100401"},{"key":"e_1_3_5_145_1","doi-asserted-by":"crossref","first-page":"1437704","DOI":"10.3389\/fcimb.2024.1437704","article-title":"Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials","volume":"14","author":"Lehtinen M","year":"2024","unstructured":"Lehtinen M, Gray P, Luostarinen T, et al. Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials. Front Cell Infect Microbiol. 2024;14:1437704.","journal-title":"Front Cell Infect Microbiol"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2377903"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060993"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00327-3"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz887"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00435-2"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz074"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101668"},{"issue":"1","key":"e_1_3_5_153_1","doi-asserted-by":"crossref","first-page":"100164","DOI":"10.1016\/j.imj.2025.100164","article-title":"Long-term protective efficacy of the Escherichia coli-produced HPV-16\/18 bivalent human papillomavirus vaccine in women vaccinated at 18\u201345 years: a 9-year follow-up study","volume":"4","author":"Jia X","year":"2025","unstructured":"Jia X, Hu S, Kuang X, et al. Long-term protective efficacy of the Escherichia coli-produced HPV-16\/18 bivalent human papillomavirus vaccine in women vaccinated at 18\u201345 years: a 9-year follow-up study. Infect Med. 2025;4(1):100164.","journal-title":"Infect Med"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-019-9547-7"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00031-3"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127015"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.04.009"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112750"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.10.041"},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2023.100313"},{"issue":"12","key":"e_1_3_5_161_1","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S1470-2045(23)00480-1","article-title":"Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9\u201314 years versus an established quadrivalent HPV vaccine in women aged 15\u201326 years in India: a randomised, active-controlled, multicentre, phase 2\/3 trial","volume":"24","author":"Sharma H","year":"2023","unstructured":"Sharma H, Parekh S, Pujari P, et al. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9\u201314 years versus an established quadrivalent HPV vaccine in women aged 15\u201326 years in India: a randomised, active-controlled, multicentre, phase 2\/3 trial. Lancet Oncol. 2023;24(12):1321\u20131333.","journal-title":"Lancet Oncol"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050511"},{"key":"e_1_3_5_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2023.09.020"},{"issue":"11","key":"e_1_3_5_164_1","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S1473-3099(23)00275-X","article-title":"Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18\u201326 years in China: a randomised blinded clinical trial","volume":"23","author":"Zhu FC","year":"2023","unstructured":"Zhu FC, Zhong GH, Huang WJ, et al. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18\u201326 years in China: a randomised blinded clinical trial. Lancet Infect Dis. 2023;23(11):1313\u20131322.","journal-title":"Lancet Infect Dis"},{"key":"e_1_3_5_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101671"},{"key":"e_1_3_5_166_1","unstructured":"World Health Organization. WHO HPV Dashboard [Internet]. Geneva (SD); 2025 [accessed 2025 Dec 2]. Available from: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases\/human-papillomavirus-vaccines-(HPV)\/hpv-clearing-house\/hpv-dashboard"},{"key":"e_1_3_5_167_1","unstructured":"GAVI. Human papillomavirus vaccine support [Internet]. 2025 [cited 2025 Sep 20]. Available from: https:\/\/www.gavi.org\/types-support\/vaccine-support\/human-papillomavirus"},{"key":"e_1_3_5_168_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13669-015-0136-9"},{"key":"e_1_3_5_169_1","unstructured":"Human papilloma virus (HPV) vaccine price data | UNICEF supply Division [Internet]. [cited 2025 Sep 14]. Available from: https:\/\/www.unicef.org\/supply\/documents\/human-papilloma-virus-hpv-vaccine-price-data"},{"key":"#cr-split#-e_1_3_5_170_1.1","unstructured":"Gavi The Vaccine Alliance. Gavi Alliance Co-financing policy version 3.0 (2023) [Internet]. GAVI"},{"key":"#cr-split#-e_1_3_5_170_1.2","unstructured":"2025 [cited 2025 Sep 24]. Available from: https:\/\/www.gavi.org\/programmes-impact\/programmatic-policies\/co-financing-policy"},{"key":"e_1_3_5_171_1","unstructured":"Immunization agenda 2030: a global strategy to leave no one behind [Internet]. 2020 [cited 2025 Sep 14]. Available from: https:\/\/www.who.int\/publications\/m\/item\/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind"},{"key":"e_1_3_5_172_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106399"},{"key":"e_1_3_5_173_1","unstructured":"Immunization Data [Internet]. WHO immunization data portal - detail page. [cited 2025 Sep 14]. Available from: https:\/\/immunizationdata.who.int\/global\/wiise-detail-page"},{"key":"e_1_3_5_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.11.008"},{"key":"e_1_3_5_175_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2460844"},{"key":"e_1_3_5_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01037-2"},{"key":"e_1_3_5_177_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127385"},{"key":"e_1_3_5_178_1","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdaf069"},{"key":"e_1_3_5_179_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2543167"},{"key":"e_1_3_5_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.05.037"},{"key":"e_1_3_5_181_1","unstructured":"Hull B Hendry A Macartney K et al. Annual immunisation coverage report 2024. National Centre for Immunisation Research and Surveillance 2024. Sydney (AU); 2025. Available online at Nov. Available online at https:\/\/ncirs.org.au\/sites\/default\/files\/2025-10\/Annual%20Immunisation%20Coverage%20Report%202024.pdf"},{"key":"e_1_3_5_182_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020258"},{"key":"e_1_3_5_183_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12919-023-00266-x"},{"key":"e_1_3_5_184_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126832"},{"key":"e_1_3_5_185_1","unstructured":"WHO. EMRO -WHO training 49 000\u00a0health workers for Pakistan\u2019s first HPV drive to protect 13 million girls from cervical cancer [Internet]. 2025 [cited 2025 Sep 24]. Available from: https:\/\/www.emro.who.int\/pak\/pakistan-news\/who-training-49-000-health-workers-for-pakistans-first-hpv-drive-to-protect-13-million-girls-from-cervical-cancer.html?layout=who_emro:news&layoutu003dwho_emro:news="},{"key":"e_1_3_5_186_1","doi-asserted-by":"publisher","DOI":"10.4274\/jtgga.galenos.2022.2022-6-6"},{"key":"e_1_3_5_187_1","unstructured":"Ervik M Lam F Laversanne M et al. Global cancer observatory: Cancer over time. Lyon (FR): International Agency for Research on Cancer. [Internet]. [cited 2024 Oct 25]. Available from: https:\/\/gco.iarc.fr\/"},{"key":"e_1_3_5_188_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-023-01149-1"},{"key":"e_1_3_5_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.07.024"},{"key":"e_1_3_5_190_1","unstructured":"A missed shot: what explains India\u2019s delay in the HPV vaccine rollout? The Wire. [Internet]. [cited 2025 Sep 24]. Available from: https:\/\/thewire.in\/health\/hpv-vaccine-india-rollout-delay-budget"},{"key":"e_1_3_5_191_1","article-title":"Challenges in HPV vaccine introduction in India \u2013 an evidence-based, pragmatic solution","volume":"301","author":"Wittenauer R","year":"2025","unstructured":"Wittenauer R, Basu P, Baussano I, et al. Challenges in HPV vaccine introduction in India \u2013 an evidence-based, pragmatic solution. HPV World [Internet]. 2025 [cited 2025 Sep 24];301. Available from: https:\/\/www.hpvworld.com\/articulos\/challenges-in-hpv-vaccine-introduction-in-india-an-evidence-based-pragmatic-solution\/?id_lang=3&save_id_lang=1","journal-title":"HPV World"},{"key":"e_1_3_5_192_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-012554"},{"key":"e_1_3_5_193_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.r1985"},{"key":"e_1_3_5_194_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177773"},{"key":"e_1_3_5_195_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pvr.2017.09.001","article-title":"Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007\u20132016","volume":"4","author":"Gallagher KE","year":"2017","unstructured":"Gallagher KE, Howard N, Kabakama S, et al. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007\u20132016. Papillomavirus Res Amst Neth. 2017;4:72\u201378.","journal-title":"Papillomavirus Res Amst Neth"},{"key":"e_1_3_5_196_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2017.06.003"},{"key":"e_1_3_5_197_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-016-3517-8"},{"key":"e_1_3_5_198_1","unstructured":"London School of Hygiene & Tropical Medicine. PATH. HPV vaccine lessons learnt. Internet. Seattle: PATH; 2016 [cited 2024 Oct 28]. Available from: https:\/\/www.path.org\/resources\/hpv-lessons-learnt\/"},{"key":"e_1_3_5_199_1","unstructured":"TechNet-21 [Internet]. [HPV evidence brief: pitfalls. Available from cited 2025 Sep 19]. Available from: https:\/\/www.technet-21.org\/en\/resources\/report\/hpv-evidence-brief-pitfalls"},{"key":"e_1_3_5_200_1","unstructured":"TechNet-21 [Internet]. [HPV evidence brief: communications. Available from cited 2025 Sep 19]. Available from: https:\/\/www.technet-21.org\/en\/resources\/report\/hpv-evidence-brief-communications"},{"key":"e_1_3_5_201_1","unstructured":"TechNet-21 [Internet]. [HPV evidence brief: sustaining programs. Available from cited 2025 Sep 19]. Available from: https:\/\/www.technet-21.org\/en\/resources\/report\/hpv-evidence-brief-sustaining-programs"},{"key":"e_1_3_5_202_1","unstructured":"TechNet-21 [Internet]. [HPV evidence brief: effective delivery. Available from cited 2025 Sep 19]. Available from: https:\/\/www.technet-21.org\/en\/resources\/report\/hpv-evidence-brief-effective-delivery"},{"key":"e_1_3_5_203_1","unstructured":"TechNet-21 [Internet]. [HPV evidence brief: preparations. Available from cited 2025 Sep 19]. Available from: https:\/\/www.technet-21.org\/en\/resources\/report\/hpv-evidence-brief-preparations"},{"key":"e_1_3_5_204_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106335"},{"key":"e_1_3_5_205_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.003"},{"key":"e_1_3_5_206_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.042"},{"key":"e_1_3_5_207_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2125383"},{"key":"e_1_3_5_208_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1150238"},{"key":"e_1_3_5_209_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0291990"},{"key":"e_1_3_5_210_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.04.025"},{"key":"e_1_3_5_211_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1112981"},{"key":"e_1_3_5_212_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2319426"},{"key":"e_1_3_5_213_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2009.50"},{"key":"e_1_3_5_214_1","doi-asserted-by":"publisher","DOI":"10.1080\/17441692.2023.2288269"},{"key":"e_1_3_5_215_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.06.074"},{"key":"e_1_3_5_216_1","volume-title":"Child and adolescent health and development [Internet]","author":"LaMontagne DS","year":"2017","unstructured":"LaMontagne DS, Cernuschi T, Yakubu A, et al. School-based delivery of vaccines to 5- to 19-year olds. In: Bundy D, de SN, Horton S, Jamison D Patton G, editors. Child and adolescent health and development [Internet]. 3rd ed. (WA) (DC): The International Bank for Reconstruction and Development\/The World Bank; 2017 [cited 2025 Sep 20]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK525257\/","edition":"3"},{"key":"e_1_3_5_217_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000101"},{"key":"e_1_3_5_218_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000130"},{"key":"e_1_3_5_219_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.074"},{"key":"e_1_3_5_220_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-15842-1"},{"key":"e_1_3_5_221_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100836"},{"key":"e_1_3_5_222_1","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czaa017"},{"key":"e_1_3_5_223_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11071246"},{"key":"e_1_3_5_224_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003357"},{"key":"e_1_3_5_225_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.11.032"},{"key":"e_1_3_5_226_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.01.024"},{"key":"e_1_3_5_227_1","unstructured":"GXP News. Russia has registered its first domestic HPV vaccine | news [Internet]. GxP news. 2025 [cited 2025 Sep 24]. Available from: https:\/\/gxpnews.net\/en\/2025\/03\/russia-has-registered-its-first-domestic-hpv-vaccine\/"},{"key":"e_1_3_5_228_1","unstructured":"GXP News. HPV vaccine is to be included in Russia\u2019s national immunization schedule by 2026 | news [Internet]. GxP news. 2024 [cited 2025 Sep 24]. Available from: https:\/\/gxpnews.net\/en\/2024\/09\/hpv-vaccine-is-to-be-included-in-russias-national-immunization-schedule-by-2026\/"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2025.2609869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T05:50:04Z","timestamp":1767160204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2025.2609869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":227,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14760584.2025.2609869"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2025.2609869","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2609869"}}